SavedAdd your journal

Journals / Türk Oftalmoloji Dergisi / 2020 / Cilt: 50 - Sayı: 1

Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma

Metastaik Melanom Tedavisinde Kullanılan Vemurafenibin Sebep Olduğu Sarkoidoz Benzeri Granulomatöz Üveit

Yüksel SÜLLÜ
Hilal Eser ÖZTÜRK
Pages
50–52
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This case is the first report that shows the clinical and angiographic features of a patient with vemurafenib-related sarcoid-like granulomatous uveitis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Vemurafenib is a potent inhibitor of genetically activated BRAF, which is responsible for tumoral proliferation in cutaneous melanoma.
📊
Key Findings & Data:A 56-year-old man receiving vemurafenib therapy presented with uveitis.
💡
Conclusion & Impact:This case is the first report that shows the clinical and angiographic features of a patient with vemurafenib-related sarcoid-like granulomatous uveitis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Vemurafenib is a potent inhibitor of genetically activated BRAF, which is responsible for tumoral proliferation in cutaneous melanoma. A 56-year-old man receiving vemurafenib therapy presented with uveitis. Over the course of the disease, he developed bilateral, granulomatous uveitis with multiple peripheral chorioretinal lesions. Serum angiotensin-converting enzyme levels increased. The patient was diagnosed with probable ocular sarcoidosis related to vemurafenib and was treated with an intravitreal dexamethasone implant. This case is the first report that shows the clinical and angiographic features of a patient with vemurafenib-related sarcoid-like granulomatous uveitis.

Özet

Vemurafenib, kutanöz melanomda tümör proliferasyonundan sorumlu genetik olarak aktifleştirilmiş BRAF’nin güçlü bir inhibitörüdür. Vemurafenib tedavisi altında olan 56 yaşında bir erkek hasta kliniğimize üveit ile başvurdu. Takiplerde, çok sayıda periferik koreoretinallezyonları olan iki taraflı granülomatöz üveit gelişti. Serum anjiyotensin dönüştürücü enzim seviyesinde artış tespit edildi. Hastaya vemurafenib ile ilişkili olası oküler sarkoidoz tanısı kondu ve intravitreal deksametazon implant ile tedavi edildi. Bu olgu, vemurafenib ile ilişkili sarkoidoz benzeri granülomatöz üveitli bir hastanın klinik ve anjiyografik özelliklerini gösteren ilk rapordur.

🔖

Cite This Article

SÜLLÜ, Y., ÖZTÜRK, H. E. (2022). Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma. Türk Oftalmoloji Dergisi, Cilt: 50 - Sayı: 1, 50–52. https://ajindex.com/articles/637830

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516
  2. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-714
  3. Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol. 2014;158:831-837
  4. Wolf SE, Meenken C, Moll AC, Haanen JB, van der Heijden MS. Severe panuveitis in a patient treated with vemurafenib for metastatic melanoma. BMC Cancer. 2013;13:561
  5. Guedj M, Queant A, Funck-Brentano E, Kramkimel N, Lellouch J, Monnet D, Longvert C, Gantzer A and Brezin AP. Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib. JAMA ophthalmology. 2014;132:1421-1425
  6. Agemy SA, Mehta AN, Pachydaki SI, Tewari A. Bilateral panuveitis in a patient on vemurafenib BRAF inhibitor therapy for stage IV melanoma. Eur J Ophthalmol. 2014;24:629-632
  7. Sızmaz S, Görkemli N, Esen E, Demircan N. A rare cause of uveitis: Vemurafenib. Turk J Ophthalmol. 2018;48:323-325
  8. Lheure C, Kramkimel N, Franck N, Laurent-Roussel S, Carlotti A, Queant A, Goldwasser F, Avril MF, Dupin N. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation. Dermatology. 2015; 231:378-384
  9. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet. 2014;383:1155-1167
  10. Herbort CP, Rao NA, Mochizuki M; members of Scientific Committee of First International Workshop on Ocular Sarcoidosis. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm. 2009;17:160-169.